In vitro activity of linezolid against clinically important gram-positive cocci in the United States: A 5-year summary of in vitro activity and resistance mechanisms from the LEADER Surveillance Program (2011-2015).
In vitro activity of linezolid against clinically important gram-positive cocci in the United States: A 5-year summary of in vitro activity and resistance mechanisms from the LEADER Surveillance Program (2011-2015). by Pfaller MA, Mendes RE, Streit JM, Hogan PA and Flamm RK published in Antimicrob. Agents Chemother. 2017; 61 (7): e00609
